Concurrent reductions in hepatic fibrosis and inflammatory markers further support a dual regulatory role, where Bifidobacterium bifidum suppresses NF-κB-mediated inflammation while activating cytoprotective antioxidant pathways. This evidence concerns the gene NFKB1 and Hepatic fibrosis.